Attiya is an attorney who focuses her practice on health law, corporate compliance, and public policy. Her experience spans both public and private sectors. She has advised clients and in-house counsel on a broad spectrum of legal matters, such as HIPAA, telehealth, attorney-client privilege, labor and employment law, consumer protection law, tort law, patient care, and billing and overpayment. She has also contributed to clean energy investment negotiations and data privacy policy development.
Attiya earned her JD from the University of Maryland Francis King Carey School of Law, where she was articles editor of the Journal of Business & Technology Law and a student attorney at the Medical-Legal Partnership Clinic. Prior to law school, she earned a BA in public policy from New York University.
Attiya is based in the Washington, DC office.
viewpoints
A Pivotal Week for Pharmaceutical Policy: Trump Administration Advances Tariff and Drug Pricing Initiatives
October 7, 2025 | Blog | By Theresa Carnegie, Stephnie John, Hassan Shaikh, Attiya S. Khan, Grace Callander, Sneha Shenoy
The first week of October 2025 marked a significant shift in U.S. drug pricing policy as the Trump administration unveiled a series of sweeping actions to deliver on his promise to lower drug prices. From President Trump’s announcement of a 100% tariff on imported branded drugs to the Trump administration’s landmark pricing deal with Pfizer and the rollout of the TrumpRx.gov direct-to-consumer (DTC) platform, last week marked an escalation in the White House’s efforts to drive down prescription drug costs and bring pharmaceutical manufacturing back to U.S. soil. Below, we provide an overview of the Trump administration’s new policies and the stakeholder responses already reshaping the broader pharmaceutical landscape.
